More than 90% of human myxoid liposarcoma (MLS) cases are associated with the chromosomal translocation, which creates a chimeric oncogene comprising part of the TLS (translocated in liposarcoma) gene (also known as FUS (fused in Ewing’s sarcoma)) and part of the CHOP (CCAAT/enhancer binding protein (C/EBP) homologous protein) gene (also called DDIT3 (DNA damage-inducible transcript 3) and GADD153 (growth arrest- and DNA damage-inducible gene 153)) (Crozat et al, 1993; Rabbitts et al, 1993; Powers et al, 2010). This evidence concerns the gene FUS and liposarcoma.